David Kraus, MD
Interventional Cardiology · Germantown, TNNPI 1225015712
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $55,510 of the $87,089 with a category attached, or 63.7%. Merck accounts for 90.5% of it on its own, with 34 other manufacturers making up the rest. Reporting peaked in 2023 at $60,964 and has fallen 96.8% since, to $1,960 in 2025.
Across 541 payments — averaging $160.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$79K
- Amgen$1K
- Novartis$892
- Pfizer$725
- Abbott$682
- Boehringer Ingelheim$496
- plus $4K from 29 others
Across 39 payments — averaging $2927.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$43K
- Merck$32K
- Bayer$31K
- Alnylam Pharmaceuticals Inc.$4K
- Novartis$4K
What the payments were for
- Speaking & faculty fees$55,51064%
- Travel & lodging$21,71925%
- Food & beverage$9,81211%
- Education$480%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 118 | $78,788 |
| Amgen | 48 | $1,109 |
| Novartis | 90 | $892 |
| Pfizer | 41 | $725 |
| Abbott | 24 | $682 |
| Boehringer Ingelheim | 30 | $496 |
| E.r. Squibb & Sons, L.L.C. | 19 | $476 |
| Alnylam Pharmaceuticals Inc. | 17 | $420 |
| Akcea Therapeutics, Inc. | 6 | $396 |
| AstraZeneca | 21 | $334 |
| Novo Nordisk | 14 | $317 |
| Johnson & Johnson | 23 | $314 |
| Bayer | 5 | $263 |
| Bridgebio Pharma, Inc. | 9 | $228 |
| Philips North America LLC | 10 | $225 |
| Sanofi-aventis U.S. LLC | 12 | $201 |
| Biotronik Inc. | 4 | $197 |
| Impulse Dynamics (USA) Inc. | 3 | $184 |
| Regeneron Healthcare Solutions, Inc. | 9 | $163 |
| Lundbeck LLC | 6 | $115 |
| Arbor Pharmaceuticals, Inc. | 5 | $89 |
| Esperion Therapeutics, Inc. | 4 | $75 |
| Lexicon Pharmaceuticals, Inc. | 4 | $68 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $48 |
| Amarin Pharma, Inc. | 3 | $43 |
| Portola Pharmaceuticals, LLC | 2 | $40 |
| Inspire Medical Systems, Inc. | 2 | $34 |
| Boston Scientific | 2 | $28 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Daxor Corporation | 1 | $23 |
| United Therapeutics Corporation | 1 | $20 |
| Vifor Pharma, Inc. | 1 | $20 |
| Baxter Healthcare | 1 | $19 |
| Scpharmaceuticals Inc. | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERQUVO$141,701
- Repatha$389
- TEGSEDI$338
- Kerendia$243
- VYNDAQEL$229
- MitraClip System$172
- MitraClip$153
- OPTIMIZER$145
- BioMonitor$144
- Solia$144
- PAMIRA$144
- Acticor 7 VR-T DX$144
- AMVIA EDGE$144
- WINREVAIR$112
How this compares
$87,089 in reported general payments places this provider in the 85th percentile of 207 interventional cardiology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 45 | $998,634 |
| EliquisApixaban | 639 | $616,465 |
| EntrestoSacubitril/Valsartan | 470 | $492,622 |
| JardianceEmpagliflozin | 413 | $337,255 |
| XareltoRivaroxaban | 259 | $280,803 |
| Repatha SureclickEvolocumab | 279 | $215,511 |
| FarxigaDapagliflozin Propanediol | 95 | $74,367 |
| MultaqDronedarone Hcl | 39 | $54,656 |
| VerquvoVericiguat | 44 | $40,917 |
| Praluent PenAlirocumab | 26 | $18,899 |
| Ezetimibe | 684 | $17,172 |
| EdarbiAzilsartan Medoxomil | 34 | $16,648 |
| BrilintaTicagrelor | 26 | $15,074 |
| Metoprolol Succinate | 929 | $14,181 |
| VascepaIcosapent Ethyl | 24 | $12,437 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $725 | $1,615,100684 claims |
| NovartisEntresto | $892 | $492,622470 claims |
| Boehringer IngelheimJardiance | $496 | $337,255413 claims |
| Johnson & JohnsonXarelto | $314 | $280,803259 claims |
| AstraZenecaFarxiga, Brilinta | $334 | $89,441121 claims |
| Sanofi-aventis U.S. LLCMultaq | $201 | $54,65639 claims |
| MerckVerquvo | $78,788 | $40,91744 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $89 | $16,64834 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 207 interventional cardiology providers in Tennessee.
Other interventional cardiology in Germantown
- Mehul PatelGermantown$382K
- Basil PaulusGermantown$67K
- James KlemisGermantown$24K
- Justin MayGermantown$23K
- Tamunoinemi Bob-ManuelGermantown$22K
- Milton AddingtonGermantown$15K
- Jimmy KerriganNashville$644K
- Kashish GoelNashville$558K
- Brian JeffersonNashville$547K
- Malcolm FosterKnoxville$413K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.